A. Allen

发表

Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors.

M. Zucchetti, F. André, J. Tabernero, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M).

H. Wakelee, L. Sequist, B. Solomon, 2014 .

A phase II trial of single-agent amrubicin (AMR) in patients with extensive disease small cell lung cancer (ED-SCLC) that is refractory or progressive within 90 days of completion of first-line platinum-based chemotherapy

D. Ettinger, R. Jotte, J. Oliver, 2008 .

A randomized phase II trial of amrubicin (AMR) vs. topotecan as second-line treatment in extensive-disease small-cell lung cancer (SCLC) sensitive to platinum-based first-line chemotherapy

R. Jotte, C. Reynolds, P. Conkling, 2007 .

First-in-human evaluation of CO-1686, an irreversible, selective, and potent tyrosine kinase inhibitor of EGFR T790M.

J. Neal, H. Wakelee, L. Sequist, 2013 .

Effects of atrasentan on disease progression and biological markers in men with metastatic hormone-refractory prostate cancer: Phase 3 study.

F. Saad, D. Dearnaley, J. Nelson, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Blockade of the CD154-CD40 costimulatory pathway prevents the development of experimental autoimmune glomerulonephritis.

C. Benjamin, C. Pusey, A. Allen, 2004, Kidney international.

Treatment with an antibody to VLA-1 integrin reduces glomerular and tubulointerstitial scarring in a rat model of crescentic glomerulonephritis.

C. Pusey, H. Cook, R. Lobb, 2002, The American journal of pathology.

Randomized multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) and a prospective evaluation of the of the association between tumor hENT1 expression and clinical outcome with gemcitabine treatment.

V. Heinemann, C. Bassi, H. Wasan, 2013 .

Effect of azacitidine (AZA) on overall survival in higher-risk myelodysplastic syndromes (MDS) without complete remission

G. Mufti, J. Bennett, P. Fenaux, 2008 .

Everolimus-Eluting Stents or Bypass Surgery for Coronary Disease

L. Sequist, L. Rolfe, A. Allen, 2015 .

Retransplantation in Alport post-transplant anti-GBM disease.

C. Pusey, A. Rees, S. Fleming, 2004, Kidney international.

Abstract A218: Pharmacokinetics of orally administered rucaparib in patients with advanced solid tumors.

R. Plummer, G. Shapiro, P. LoRusso, 2013 .

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.

Anne Floquet, Andrew R Allen, James X. Sun, 2017, The Lancet. Oncology.

Endothelial expression of VCAM-1 in experimental crescentic nephritis and effect of antibodies to very late antigen-4 or VCAM-1 on glomerular injury.

D. Haskard, H. Cook, A. Karkar, 1999, Journal of immunology.

Rociletinib in EGFR-mutated non-small-cell lung cancer.

J. Neal, H. Wakelee, L. Sequist, 2015, The New England journal of medicine.

Results of ARIEL2: A Phase 2 trial to prospectively identify ovarian cancer patients likely to respond to rucaparib using tumor genetic analysis.

R. Yelensky, A. Tinker, A. Oza, 2015 .

Blocking VLA-4 Prevents Progression of Experimental Crescentic Glomerulonephritis

C. Pusey, H. Cook, R. Lobb, 2003, Nephron Experimental Nephrology.

Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor.

S. Digumarthy, A. Iafrate, M. Mino‐Kenudson, 2015, Cancer discovery.

A phase I study of oral rucaparib in combination with carboplatin.

Y. Drew, R. Plummer, C. Michie, 2013 .

Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686)

C. Paweletz, P. Angenendt, H. Wakelee, 2016, Clinical Cancer Research.

A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocarcinoma and negative tumor hENT1 expression.

M. Lowery, D. Ryan, M. Saif, 2014, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

VCAM-1 has a tissue-specific role in mediating interleukin-4-induced eosinophil accumulation in rat models: evidence for a dissociation between endothelial-cell VCAM-1 expression and a functional role in eosinophil migration.

S. Nourshargh, D. Haskard, R. Lobb, 2000, Blood.

VCAM-1 on Glomerular Injury of Antibodies to Very Late Antigen-4 or Experimental Crescentic Nephritis and Effect Endothelial Expression of VCAM-1 in

C. Pusey, D. Haskard, A. Karkar, 1999 .

Prostate-specific antigen doubling time as a predictor of prostate cancer disease progression and survival

J. Nelson, D. Sleep, J. Isaacson, 2004 .

Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer.

L. Sequist, L. Rolfe, A. Allen, 2015, The New England journal of medicine.

Benefit of Atrasentan in Men with Hormone Refractory Prostate Cancer Metastatic to Bone.

A. Lipton, D. Sleep, J. Isaacson, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

965PEvaluation of tumour responses and olaparib efficacy in platinum-sensitive relapsed ovarian cancer (PSROC) patients (pts) with or without measurable disease in the SOLO2 trial (ENGOT Ov-21)

A. Oza, C. Scott, I. Vergote, 2017 .

EFFECT OF AZACITIDINE (AZA) vs LOW-DOSE ARA-C (LDAC) ON OVERALL SURVIVAL (OS), HEMATOLOGIC RESPONSE, TRANSFUSION INDEPENDENCE, AND SAFETY IN PATIENTS (PTS) WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (MDS)

H. Dombret, G. Mufti, P. Fenaux, 2008 .

Corrections to "Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors".

M. Zucchetti, F. André, J. Tabernero, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Benefit of Atrasentan in Men with Hormone Refractory Prostate Cancer Metastatic to Bone

A. Lipton, D. Sleep, J. Isaacson, 2004 .